Translator Disclaimer
13 March 2014 Effects of laser immunotherapy on late-stage, metastatic breast cancer patients in a Phase II clinical trial
Author Affiliations +
Proceedings Volume 8944, Biophotonics and Immune Responses IX; 89440I (2014)
Event: SPIE BiOS, 2014, San Francisco, California, United States
Laser immunotherapy (LIT), a novel technique with a local intervention to induce systemic antitumor effects, was developed to treat metastatic cancers. The pre-clinical studies of LIT have shown its unique characteristics in generating a specific antitumor immunity in treating metastatic tumors in rats and mice. For late-stage, metastatic breast cancer patients, who were considered to be out of other available treatment options, we conducted a small Phase II clinical trial using LIT starting in 2009 in Lima, Peru. This Phase II study was closed in December of 2012, as acknowldged by the Ministry of Health (MOH) of Peur letter 438-2014-OGITT/INS dated March 5th, 2014. Ten patients were enrolled and received LIT in one or multiple 4-week treatment cycles. At the study closing date, four patients were alive and two of them remained cancer free. Here, following the successful conclusion of our Phase II study, we report the clinical effects of LIT on metastatic breast cancer patients. Specifically, we present the overall status of all the patients three years after the treatment and also the outcomes of two long-term surviving patients.
© (2014) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Gabriela L. Ferrel, Feifan Zhou, Xiaosong Li, Tomas Hode, Robert E. Nordquist, Luciano Alleruzzo, and Wei R. Chen "Effects of laser immunotherapy on late-stage, metastatic breast cancer patients in a Phase II clinical trial", Proc. SPIE 8944, Biophotonics and Immune Responses IX, 89440I (13 March 2014);

Back to Top